Drug Cost Management Report - The FDA has approved Abilify™ tablets , a schizophrenia treatment by Bristol-Myers Squibb and Otsuka Pharmaceuticals - aripiprazole - Product News in Brief
* The FDA has approved Abilify[TM] tablets (aripiprazole), a schizophrenia treatment by Bristol-Myers Squibb and Otsuka Pharmaceuticals. There is no cure for the devastating brain disorder affecting 2.2 million Americans, but it is treatable, and Abilify has demonstrated a favorable side-effect profile in clinical trials.
Related Results
Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionNew ABILIFY formulation
Psychiatric drugs account for over 12% of PBM spending, higher than any other single therapeutic category, according to AIS’ third quarter 2002 survey of PBMs. Information: www.abilify.com.
COPYRIGHT 2002 Atlantic Information Services, Inc.
COPYRIGHT 2003 Gale Group
